Effects of antisense oligodeoxynucleotide to follicle-stimulating hormone receptor on the cell proliferation and apoptosis in cells derived from human ovarian mucinous cystadenocarcinoma in Vitro

Abstract

The human ovarian mucinous cystadenocarcinoma (hOMC) cells were co-cultured with antisense oligodeoxynucleotide (antisense ODN), nonsense ODN, and follicle-stimulating hormone (FSH) at different concentrations for the purpose of observing the effects of antisense ODN to FSH receptor (FSHR) on the proliferation and apoptosis of cultured hOMC cells in vitro. The inhibitory rates of growth were measured by using MTT method on the 2nd, 4th, 6th, 8th and 10th days after the interference of antisense ODN, nonsense ODN, and FSH, respectively. The apoptotic rates and the cell cycles were determined by means of flow cytometry, the apoptosis indexes were detected by using TUNEL, and the expression of caspase-3 was measured by using SP immunohistochemistry. Compared with that in the control group, the proliferative activity of hOMC cells was increased obviously in FSH groups (P<0.05 or P<0.01), decreased distinctly in antisense ODN groups (P<0.05 or P<0.01), and unchanged in nonsense ODN groups, respectively. Meanwhile, antisense ODN could significantly antagonize the FSH-promoted cell proliferative activity (P<0.01). Compared with those in the control group, the apoptotic rates and the expression of caspase-3 were dramatically increased in the mid-and high-dose antisense ODN groups (P<0.05 or P<0.01), while the number of cells in G₁/G₀ phase was significantly decreased and that in S phase distinctly increased (P<0.01). There was no change in nonsense ODN groups (P>0.05). It was suggested that FSH may improve the development of hOMC cells. However, antisense ODN could inhibit proliferative activity and the FSH-promoted proliferative activity in hOMC cells, at the same time, antisense ODN could inhibit hOMC cell growth by inducing apoptosis.

Keywords

follicle-stimulating hormone receptor / antisense oligodeoxynucleotide / ovarian neoplasm / cell proliferation / apoptosis

References

[1] WangJ., LynneL., VinitaP., et al.. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int J Cancer, 2003, 103: 328-334

[2] SyedV., UlinskiG., MolS. C., et al.. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res, 2001, 61: 6768-6776

[3] ShenZ., FangM.. The biochemistry characteristics of FSHR and its expression and regulation. Modern J Obstet Gynecol Advanced (Chinese), 2004, 13: 137-139

[4] ZhengW., LuJ., LuoF., et al.. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinzing hormone. Gynecol Oncol, 2000, 76: 80-88

[5] SteinC. A., MoriK., LokeS. L., et al.. Phosphorothioate and normal oligodeoxyribonucleotides with 50-linked acridine: Characterization and preliminary kinetics of cellular uptake. Gene, 1988, 72: 333-341

[6] ZhuC. H., WangY. F., NixonM. D., et al.. Antisense oligodeoxynucleotide inhibits expression of recombinant porcine follicle-stimulating hormone receptor. Mol Reprod Dev, 2003, 65: 188-193

[7] ZhuC. H., XiongZ. M., XiaoH. Z.. The effects of antisense oligodeoxynucleotide on the expression of recombinant porcine follicle-stimulating hormone receptor (Chinese). National J Androl, 2000, 3: 146-149

[8] LiS., LiuH. F., WangL., et al.. Effects of antisense oligodeoxynucleotide to follicle-stimulating hormone receptor on the expression of proliferating cell nuclear antigen and vascular endothelial growth factor in cultured cells derived from human ovarian mucinous cystadenocarcinoma. J Huazhong Univ Sci and Technol (Med Sci), 2006, 26: 111-115

[9] McElenyK., CoffeyR., MorrisseyC., et al.. An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to Fas and TNF-alpha mediated apoptosis. Prostate, 2004, 59: 419-425

[10] BanderaC. A., CramerD. W., FreiedmanA. J., et al.. Fertility therapy in the setting of a history of invasive epithelial ovarian cancer. Gynecol Oncol, 1995, 58: 116-119

[11] KraemerS., JaegerW. H., LangN.. Growth regulation effects of gonadotropin induced steroidogenic response in human ovarian cancer. Anticancer Res, 2001, 21: 2005-2010

[12] HuangC. F., LiuD. Y., ShenK.. Follicle stimulating hormone inhibits Cisplatin induced apoptosis in ovarian tumor cells. Acta Academic Medicinae Sinicae (Chinese), 2003, 25: 447-450

[13] HuangC. F., LiuD. Y., XuW. H., et al.. Protective effect of follicle stimulating hormone on apoptosis of human epithelial ovarian cancer cells induced by Cisplatin. Acta Academic Medicinae Sinicae (Chinese), 2003, 25: 444-446

[14] SaikumarP., DongZ., MikhailowV., et al.. Apoptosis: definition, mechanism, and relevance to disease. Am J Med, 1999, 107: 489-506